Paper Details

  1. Home
  2. Paper Details

Drug safety evaluation of vemurafenib in the treatment of melanoma.

Author: KimKevin B, NowrooziSasan, TsaiKenneth Y

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Vemurafenib, a targeted therapy for V600 BRAF-mutant advanced melanoma, has shown a clinical response rate of approximately 50% and a median progression-free survival duration of 6-7 months. While vemurafenib does not induce life-threatening toxicity frequently associated with conventional chemotherapy, it is associated with skin toxicities.
Paper Details　
Original Abstract of the Article :
Nearly 50% of melanomas harbor a BRAF mutation, and vemurafenib has shown a clinical response rate of approximately 50% and a median progression-free survival duration of ∼ 6 - 7 months in patients with V600 BRAF-mutant advanced melanoma. Based on a Phase III study demonstrating a survival advantage...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14740338.2013.813017

データ提供：米国国立医学図書館（NLM）

Vemurafenib: A Beacon of Hope for Melanoma Treatment

The quest for [effective treatments for melanoma] is an ongoing battle in [oncology]. This study examines the safety and efficacy of [vemurafenib], a targeted therapy specifically designed for patients with [V600 BRAF-mutant advanced melanoma]. The study highlights the [clinical response rate] and [progression-free survival] observed in patients treated with vemurafenib, demonstrating its potential as a valuable therapeutic option.

Vemurafenib: A Promising Treatment for BRAF-Mutant Melanoma

The study's findings demonstrate the significant impact of [vemurafenib] on the management of [BRAF-mutant advanced melanoma]. The drug has shown impressive results in [clinical trials], offering a promising alternative to [conventional chemotherapy]. While vemurafenib has [fewer life-threatening toxicities], it is important to [carefully monitor] patients for potential [adverse events], particularly [skin toxicities].

Melanoma: A Complex and Challenging Enemy

Melanoma is a [serious disease] that requires [vigilant monitoring and early detection]. While [vemurafenib] offers hope for patients with [BRAF-mutant melanoma], it is crucial to [understand the risks and benefits] of this treatment. [Consulting with a medical professional] is essential for determining the best course of action for your individual situation.

Dr.Camel's Conclusion

Vemurafenib's arrival in the realm of melanoma treatment is like a refreshing oasis in a sun-scorched desert. This targeted therapy holds the potential to significantly improve the lives of patients with BRAF-mutant melanoma. Remember, just like the desert's resilience, our fight against melanoma requires perseverance and a commitment to finding effective solutions.

Date :
  1. Date Completed 2014-04-02
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

23800008

DOI: Digital Object Identifier

10.1517/14740338.2013.813017

Related Literature

Article Analysis
・Effective treatment of drug safety
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.